Citations

Showing 10 of 108104 citations.

Outcomes of cardiac surgery in nonagenarians
Elsisy, Mohamed F. , Stulak, John M., Stephens, Elizabeth H. , Alkhouli, Mohamad A, Stephens, Elizabeth H , Schaff, Hartzell V. , Crestanello, Juan A. , Alkhouli, Mohamad

Mayo Clinic

Journal of Cardiac Surgery | March 14, 2022 | Volume: 37 | Issue: 6 | Pages: 1664-1670

10.1111/jocs.16396 | PMID 35285545 Get It

Clinical Course and Impact of Immune Checkpoint Inhibitor Colitis Resembling Microscopic Colitis
Fredrick, Thomas , Ramos, Guilherme Piovezani , Neto, Manuel B. Braga , Kane, Sunanda V. , Faubion, William A. , Loftus, Edward V. , Pardi, Darrell S. , Pasha, Shabana F., Farraye, Francis A. , Zhang, Lizhi , Raffals, Laura E. , Fredrick, Thomas W , Ramos, Guilherme P , Braga Neto, Manuel B , Kane, S , Loftus, Edward V , Farraye, Francis A

Mayo Clinic

Crohn's & Colitis 360 | March 14, 2022 | Volume: 4 | Issue: 2 | Pages: No page available

10.1093/crocol/otac008 | PMID 36777041 Get It

Abstract Background Microscopic colitis (MC) is suspected to result from increased immune activity in gut mucosa. Immune checkpoint inhibitors (ICIs) treat cancer by activating the immune system, and further investigation is needed regarding their role in the development of MC. Methods A retrospective case series investigated cases of endoscopically and histologically confirmed MC developing after administration of ICIs. Clinical notes and medication administration records were reviewed for demographics, symptom duration, and treatment response. Results Nineteen cases of de novo MC were identified, with 95% of cases requiring steroid treatment, 53% presenting with hospitalization, and colitis-related mortality in 1 individual. Symptom onset occurred a median of 160 days after initiation of ICI therapy and 53 days after their most recent dose of therapy. Patients had a median of 125 days of symptoms, and ICI therapy was held in 70% of individuals due for treatment. Conclusions MC can develop after ICI administration, and presents with severe symptoms, often requiring hospitalization and steroid treatment. In certain individuals this can require a prolonged treatment course of steroid therapy or immunomodulators. Individuals developing diarrhea after ICI therapy warrant thorough workup including endoscopy and rapid treatment initiation given the disease severity observed in this series.
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
Lheureux, Stéphanie , Konstantinopoulos, Panagiotis A. , Wang, Ben X. , Gadalla, Ramy , Block, Matthew S. , Gaillard, Stéphanie , McHale, Michael , Werner, Theresa L. , Duska, Linda , Kehoe, Siobhan M., Colombo, Ilaria , Wang, Lisa , Wildman, Rachel P., Soleimani, Shirin , Lien, Scott , Wright, John, Pugh, Trevor J. , Pugh, Trevor J , Konstantinopoulos, Panagiotis A , Gaillard, Stéphanie , Matei, Daniela , Jewell, Andrea , McCourt, Carolyn Kay , Temkin, Sarah M. , Girda, Eugenia , Backes, Floor , Li, Xuan , Wildman, Rachel, Wright, John, Ohashi, Pamela S. , Brooks, David G. , Fleming, Gini F.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 14, 2022 | Volume: 10 | Issue: 3 | Pages: e004233

10.1136/jitc-2021-004233 | PMID 35288469 Get It

Background Combining immunotherapy and antiangiogenic agents is a promising treatment strategy in endometrial cancer. To date, no biomarkers for response have been identified and data on post-immunotherapy progression are lacking. We explored the combination of a checkpoint inhibitor (nivolumab) and an antiangiogenic agent (cabozantinib) in immunotherapy-naïve endometrial cancer and in patients whose disease progressed on previous immunotherapy with baseline biopsy for immune profiling. Patients and methods In this phase II trial (ClinicalTrials.gov NCT03367741, registered December 11, 2017), women with recurrent endometrial cancer were randomized 2:1 to nivolumab with cabozantinib (Arm A) or nivolumab alone (Arm B). The primary endpoint was Response Evaluation Criteria in Solid Tumors-defined progression-free survival (PFS). Patients with carcinosarcoma or prior immune checkpoint inhibitor received combination treatment (Arm C). Baseline biopsy and serial peripheral blood mononuclear cell (PBMC) samples were analyzed and associations between patient outcome and immune data from cytometry by time of flight (CyTOF) and PBMCs were explored. Results Median PFS was 5.3 (90% CI 3.5 to 9.2) months in Arm A (n=36) and 1.9 (90% CI 1.6 to 3.4) months in Arm B (n=18) (HR=0.59, 90% CI 0.35 to 0.98; log-rank p=0.09, meeting the prespecified statistical significance criteria). The most common treatment-related adverse events in Arm A were diarrhea (50%) and elevated liver enzymes (aspartate aminotransferase 47%, alanine aminotransferase 42%). In-depth baseline CyTOF analysis across treatment arms (n=40) identified 35 immune-cell subsets. Among immunotherapy-pretreated patients in Arm C, non-progressors had significantly higher proportions of activated tissue-resident (CD103+CD69+) ɣδ T cells than progressors (adjusted p=0.009). Conclusions Adding cabozantinib to nivolumab significantly improved outcomes in heavily pretreated endometrial cancer. A subgroup of immunotherapy-pretreated patients identified by baseline immune profile and potentially benefiting from combination with antiangiogenics requires further investigation.
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study
Naing, Aung , Powderly, John D. , Nemunaitis, John , Luke, Jason J. , Mansfield, Aaron S. , Messersmith, Wells A. , Sahebjam, Solmaz , LoRusso, Patricia , Garrido‐Laguna, Ignacio , Leopold, Lance, Geschwindt, Ryan, Ding, Kai , Smith, Michael , Nemunaitis, John J , Mansfield, Aaron S , Luke, Jason J , Berlin, Jordan D.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 14, 2022 | Volume: 10 | Issue: 3 | Pages: e004223

10.1136/jitc-2021-004223 | PMID 35288468 Get It

Background This phase I multicenter study was designed to evaluate the safety, tolerability, efficacy, and translational effects on the tumor microenvironment of itacitinib (Janus-associated kinase 1 (JAK1) inhibitor) in combination with epacadostat (indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor) or parsaclisib (phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor). Methods Patients with advanced or metastatic solid tumors were enrolled and received itacitinib (100–400 mg once a day) plus epacadostat (50–300 mg two times per day; group A), or itacitinib (100–400 mg once a day) plus parsaclisib or parsaclisib monotherapy (0.3–10 mg once a day; group B). Results A total of 142 patients were enrolled in the study. The maximum tolerated dose was not reached for either the combination of itacitinib plus epacadostat (n=47) or itacitinib plus parsaclisib (n=90). One dose-limiting toxicity of serious, grade 3 aseptic meningitis was reported in a patient receiving itacitinib 300 mg once a day plus parsaclisib 10 mg once a day, which resolved when the study drugs were withdrawn. The most common treatment-related adverse events among patients treated with itacitinib plus epacadostat included fatigue, nausea, pyrexia, and vomiting, and for patients treated with itacitinib plus parsaclisib were fatigue, pyrexia, and diarrhea. In the itacitinib plus epacadostat group, no patient had an objective response. Among patients receiving itacitinib 100 mg once a day plus parsaclisib 0.3 mg once a day, three achieved partial response for an objective response rate (95% CI) of 7.1% (1.50 to 19.48). Treatment with itacitinib plus epacadostat demonstrated some increase in tumor CD8+ T cell infiltration and minor changes in six plasma proteins, whereas treatment with itacitinib plus high-dose parsaclisib resulted in downregulation of 20 plasma proteins mostly involved in immune cell function, with no observed change in intratumoral CD8+ T cell infiltration. Conclusion Adverse events with JAK1 inhibition combined with either IDO1 or PI3Kδ inhibition were manageable, but the combinations demonstrated limited clinical activity or enhancement of immune activation in the tumor microenvironment. Trial registration number NCT02559492.
Patient Perspectives on Integrating Risk Prediction Into Kidney Care: Opinion Piece
Sparkes, Dwight , Lee, Loretta, Rutter, Blair, Harasemiw, Oksana , Thorsteinsdottir, Bjoerg , Tangri, Navdeep , Thorsteinsdottir, Bjorg

Mayo Clinic

Canadian Journal of Kidney Health and Disease | March 14, 2022 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/20543581221084522 | PMID 35646376 Get It

Although Chronic Kidney Disease is common, only a relatively small proportion of individuals will reach kidney failure requiring dialysis or transplantation. Validated risk equations using routine laboratory tests have been developed that can easily be used at the bedside to help clinicians accurately predict the risk of kidney failure in their patient population, in turn informing patient-centered conversations, guiding appropriate nephrology referrals, improving the timing of dialysis treatment planning, and identifying individuals who are most likely to benefit from interventions. In this article, individuals living with kidney disease share why access to individualized prediction of kidney failure risk can help patients manage their disease and why it should be considered an essential component of kidney care.
Cognitive predictors of social adjustment in pediatric brain tumor survivors treated with photon versus proton radiation therapy
Warren, Emily , Cirino, Paul T. , Child, Amanda , Lupo, Philip J. , Grosshans, David R. , Paulino, Arnold C. , Okcu, M. Fatih , Ris, M. Douglas , Mahajan, Anita , Viana, Andres G. , Chintagumpala, Murali , Kahalley, Lisa S. , Warren, Emily A H , Raghubar, Kimberly P , Child, Amanda E , Paulino, Arnold C , Kahalley, Lisa S , Minard, Charles G.

Mayo Clinic

Pediatric Blood & Cancer | March 14, 2022 | Volume: 69 | Issue: 6 | Pages: No page available

10.1002/pbc.29645 | PMID 35285129 Get It

AbstractBackgroundPediatric brain tumor survivors are at risk for poor social outcomes. It remains unknown whether cognitive sparing with proton radiotherapy (PRT) supports better social outcomes relative to photon radiotherapy (XRT). We hypothesized that survivors treated with PRT would outperform those treated with XRT on measures of cognitive and social outcomes. Further, we hypothesized that cognitive performance would predict survivor social outcomes.ProcedureSurvivors who underwent PRT (n = 38) or XRT (n = 20) participated in a neurocognitive evaluation >1 year post radiotherapy. Group differences in cognitive and social functioning were assessed using analysis of covariance (ANCOVA). Regression analyses examined predictors of peer relations and social skills.ResultsAge at evaluation, radiation dose, tumor diameter, and sex did not differ between groups (all p > .05). XRT participants were younger at diagnosis (XRT M = 5.0 years, PRT M = 7.6 years) and further out from radiotherapy (XRT M = 8.7 years, PRT M = 4.6 years). The XRT group performed worse than the PRT group on measures of processing speed (p = .01) and verbal memory (p < .01); however, social outcomes did not differ by radiation type. The proportion of survivors with impairment in peer relations and social skills exceeded expectation; χ2(1) = 38.67, p < .001; χ2(1) = 5.63, p < .05. Household poverty predicted peer relation difficulties (t = 2.18, p < .05), and verbal memory approached significance (t = −1.99, p = .05). Tumor diameter predicted social skills (t = −2.07, p < .05).ConclusionsRegardless of radiation modality, survivors are at risk for social challenges. Deficits in verbal memory may place survivors at particular risk. Results support monitoring of cognitive and social functioning throughout survivorship, as well as consideration of sociodemographic risk factors.
Hypothermia Therapy for Traumatic Spinal Cord Injury: An Updated Review
Ransom, Seth C. , Brown, Nolan J. , Pennington, Zach , Lakomkin, Nikita , Mikula, Anthony L. , Bydon, Mohamad , Elder, Benjamin D. , Pennington, Zachary A, Pennington, Zach

Mayo Clinic

Journal of Clinical Medicine | March 13, 2022 | Volume: 11 | Issue: 6 | Pages: 1585

10.3390/jcm11061585 | PMID 35329911 Get It

Although hypothermia has shown to protect against ischemic and traumatic neuronal death, its potential role in neurologic recovery following traumatic spinal cord injury (TSCI) remains incompletely understood. Herein, we systematically review the safety and efficacy of hypothermia therapy for TSCI. The English medical literature was reviewed using PRISMA guidelines to identify preclinical and clinical studies examining the safety and efficacy of hypothermia following TSCI. Fifty-seven articles met full-text review criteria, of which twenty-eight were included. The main outcomes of interest were neurological recovery and postoperative complications. Among the 24 preclinical studies, both systemic and local hypothermia significantly improved neurologic recovery. In aggregate, the 4 clinical studies enrolled 60 patients for treatment, with 35 receiving systemic hypothermia and 25 local hypothermia. The most frequent complications were respiratory in nature. No patients suffered neurologic deterioration because of hypothermia treatment. Rates of American Spinal Injury Association (AIS) grade conversion after systemic hypothermia (35.5%) were higher when compared to multiple SCI database control studies (26.1%). However, no statistical conclusions could be drawn regarding the efficacy of hypothermia in humans. These limited clinical trials show promise and suggest therapeutic hypothermia to be safe in TSCI patients, though its effect on neurological recovery remains unclear. The preclinical literature supports the efficacy of hypothermia after TSCI. Further clinical trials are warranted to conclusively determine the effects of hypothermia on neurological recovery as well as the ideal means of administration necessary for achieving efficacy in TSCI.
Cell Type-Specific Induction of Inflammation-Associated Genes in Crohn’s Disease and Colorectal Cancer
Saul, Dominik , Barros, Luísa Leite , Wixom, Alexander Q. , Gellhaus, Benjamin , Gibbons, Hunter R. , Faubion, William A. , Kosinsky, Robyn Laura , Leite Barros, Luísa, Kosinsky, Robyn Laura , Wixom, Alexander Q , Saul, Dominik

Mayo Clinic

International Journal of Molecular Sciences | March 13, 2022 | Volume: 23 | Issue: 6 | Pages: 3082

10.3390/ijms23063082 | PMID 35328501 Get It

Based on the rapid increase in incidence of inflammatory bowel disease (IBD), the identification of susceptibility genes and cell populations contributing to this condition is essential. Previous studies suggested multiple genes associated with the susceptibility of IBD; however, due to the analysis of whole-tissue samples, the contribution of individual cell populations remains widely unresolved. Single-cell RNA sequencing (scRNA-seq) provides the opportunity to identify underlying cellular populations. We determined the enrichment of Crohn’s disease (CD)-induced genes in a publicly available Crohn’s disease scRNA-seq dataset and detected the strongest induction of these genes in innate lymphoid cells (ILC1), highly activated T cells and dendritic cells, pericytes and activated fibroblasts, as well as epithelial cells. Notably, these genes were highly enriched in IBD-associated neoplasia, as well as sporadic colorectal cancer (CRC). Indeed, the same six cell populations displayed an upregulation of CD-induced genes in a CRC scRNA-seq dataset. Finally, after integrating and harmonizing the CD and CRC scRNA-seq data, we demonstrated that these six cell types display a gradual increase in gene expression levels from a healthy state to an inflammatory and tumorous state. Together, we identified cell populations that specifically upregulate CD-induced genes in CD and CRC patients and could, therefore, contribute to inflammation-associated tumor development.
A Preliminary Report of Network Electroencephalographic Measures in Primary Progressive Apraxia of Speech and Aphasia
Utianski, Rene L. , Caviness, John N., Duffy, Joseph R. , Clark, Heather M. , Whitwell, Jennifer L. , Josephs, Keith A. , Duffy, Joseph R , Clark, Heather M , Utianski, Rene L , Botha, Hugo , Worrell, Gregory A.

Mayo Clinic

Brain Sciences | March 13, 2022 | Volume: 12 | Issue: 3 | Pages: 378

10.3390/brainsci12030378 | PMID 35326334 Get It

The objective of this study was to characterize network-level changes in nonfluent/agrammatic Primary Progressive Aphasia (agPPA) and Primary Progressive Apraxia of Speech (PPAOS) with graph theory (GT) measures derived from scalp electroencephalography (EEG) recordings. EEGs of 15 agPPA and 7 PPAOS patients were collected during relaxed wakefulness with eyes closed (21 electrodes, 10–20 positions, 256 Hz sampling rate, 1–200 Hz bandpass filter). Eight artifact-free, non-overlapping 1024-point epochs were selected. Via Brainwave software, GT weighted connectivity and minimum spanning tree (MST) measures were calculated for theta and upper and lower alpha frequency bands. Differences in GT and MST measures between agPPA and PPAOS were assessed with Wilcoxon rank-sum tests. Of greatest interest, Spearman correlations were computed between behavioral and network measures in all frequency bands across all patients. There were no statistically significant differences in GT or MST measures between agPPA and PPAOS. There were significant correlations between several network and behavioral variables. The correlations demonstrate a relationship between reduced global efficiency and clinical symptom severity (e.g., parkinsonism, AOS). This preliminary, exploratory study demonstrates potential for EEG GT measures to quantify network changes associated with degenerative speech–language disorders.